Immunocore
IMCR
Immunocore (IMCR) news
Recent news
Immunocore - Achieves target enrollment in Tebe-AM trial with Kimmtrak in advanced melanoma
Immunocore Holdings plc (Nasdaq: IMCR) has announced that it has achieved target enrollment in TEBE-AM . The trial, which was initially designed as an adaptive Phase 2/3 study, was converted into a Phase 3 trial following consultation with the U.S. Food and Drug Administration (FDA). The decision…
AInvest Wire · Sep 14, 2026Immunocore - Topline overall survival data from Tebe-AM trial expected by end of 2026
AInvest Wire · Sep 14, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.